Industry: Next-Gen Sequencing Draft Guidances Have Good Ideas But Need Tweaks
Executive Summary
The 37 groups and individuals who submitted comments on FDA’s two draft guidances on next-generation sequencing issued in July expressed appreciation for the thinking behind the guidances, but found bones to pick with some details.
You may also be interested in...
Diagnostics In 2016: From Alere To Zika
No significant trends emerged in diagnostics M&A or financing this past year, which did see the introduction of several government-funded initiatives, elements of which will bolster diagnostics innovation. As in other sectors of health care, the biggest question is how the incoming Trump administration could change US regulatory and funding policies.
Liquid Biopsy, Particle-Beam Radiotherapy Get 'Moonshot' Commitments
The White House announced 36 new project commitments under its ongoing Cancer Moonshot oncology initiative, including an ambitious project to create an open liquid-biopsy database and a NASA-NCI collaboration to explore the benefits of particle-beam radiotherapy.
US FDA's Next-Gen Sequencing Guidances: One Stop On A Pathway
Two recent next-generation sequencing draft guidances have been positively received so far by industry and clinical research groups. But for FDA's ideas to play out, more databases will need to be populated and more standards developed, agency officials say. There are also more guidances to come on different types of NGS tests. Read our coverage below, and also listen to our podcast interview with FDA's Elizabeth Mansfield.